What OATS delivers that other cartilage repairs don't

For an active adult with a painful focal cartilage defect, the instinctive question is whether a simpler, less invasive option will do the job just as well. In many cases, the honest answer is no — and the reason comes down to tissue biology.

OATS works by harvesting cylindrical plugs of bone and cartilage from a lower-load region of the patient's own knee and press-fitting them into the damaged area. What arrives at the defect site is genuine hyaline cartilage — the same dense, well-organised tissue that lines a healthy joint. Hyaline cartilage is built for sustained, repetitive loading: it distributes force efficiently and resists the wear that comes with sport, running, or physically demanding work.

Some other techniques, notably microfracture, stimulate the body to fill a defect with fibrocartilage — a structurally inferior tissue that handles impact loading less well and tends to soften over time. That single biological difference underpins much of the long-term outcome gap between the procedures.

OATS is also completed in a single operative session: there is no cell-culture wait between stages and no second procedure to implant harvested cells.

The procedure is designed for focal, contained defects — typically around 1–2 cm², or up to approximately 4 cm² when a multi-plug mosaicplasty technique is used. It is not appropriate for diffuse or end-stage osteoarthritis, where cartilage loss is too widespread for a targeted autograft approach.

Long-term success rates from the strongest available evidence

The most comprehensive long-term data come from Pareek et al.'s 2016 systematic review — cited more than 140 times in the surgical literature — which tracked patients to a mean of 10.2 years. Seventy-two per cent achieved successful clinical outcomes across that period.

The same review records a 28% failure rate and a 19% reoperation rate over the same window. Both figures carry equal weight: OATS produces durable results in the majority, but roughly one patient in four will not see that outcome sustained at a decade.

Three variables consistently predict who falls into the less successful group: older patient age at the time of surgery, a history of prior surgery on the same knee, and a larger cartilage defect. Each is, to a meaningful degree, timing-sensitive. Patients who reach OATS before the lesion has expanded — and before the knee has been through earlier, less durable procedures — start from a measurably more favourable position. The implication is practical: early specialist review matters.

On head-to-head evidence: high-quality randomised controlled trials directly comparing OATS with microfracture in a knee-specific athletic cohort remain limited; most long-term comparison data derive from systematic reviews combining different study designs. That methodological gap does not undermine the directional consistency across available studies, but it does mean that expected outcomes for any individual patient are best interpreted through specialist assessment rather than population averages alone.

Return to sport after OATS

Eighty-two-point-nine days. That is the mean return-to-sport time recorded by Werner (2017, PMC5400208) in 20 competitive athletes who underwent osteochondral autograft transfer on an accelerated rehabilitation protocol — roughly two and three-quarter months from surgery to competitive activity. Every one of those athletes returned to their previous level of play; satisfaction was 100% and mean postoperative IKDC score reached 84.5.

That figure sits at the faster end of the published range. A large systematic review of 52 studies covering more than 2,300 athletes places the overall cartilage-restoration return-to-sport rate at approximately 80%, with OATS averaging around 6.6 months — still among the highest-performing procedures across the field. The gap between 82.9 days and 6.6 months reflects protocol variation, lesion complexity, and sport type rather than any inconsistency in the underlying outcome signal.

The strongest headline figure comes from a 2024 systematic review of 470 athletes with osteochondritis dissecans lesions treated by OAT, which found a 97% return-to-sport rate with 87% achieving excellent patient-reported scores — though this review pooled mixed-joint data including elbow as well as knee cases, so it is best read as a directional upper bound rather than a knee-specific guarantee.

Across all three datasets, one variable beyond surgical technique itself recurs: rehabilitation protocol quality. An accelerated, well-structured programme appears to compress recovery without compromising outcome, which means the post-operative plan matters as much as the procedure when setting realistic expectations.

Why microfracture is now a historical comparator for active patients

The clinical gap between the two procedures is stark. In athletic populations, OATS achieves good-to-excellent outcomes in 82–96% of cases; microfracture manages 52–67%. At long-term follow-up, failure rates diverge further still — below 15% for OATS against 32–38% or more for microfracture.

Microfracture's historical appeal rested on two genuine advantages: a simpler operative technique and a shorter permitted return-to-sport window of three to six months, compared with a mean of 7.1 months for standard OAT (Arthroscopy Journal, 2015). For clinicians managing high case volumes, and for patients anxious to return to training quickly, that was a meaningful practical consideration.

The durability problem has progressively narrowed that appeal. The fibrocartilage microfracture produces tends to break down at two to three years under sustained athletic loading — a pattern now well documented across studies. More consequentially for treatment sequencing, perforating the subchondral bone plate introduces structural change that can compromise outcomes if more advanced repair becomes necessary later. This is one reason prior ipsilateral surgery — frequently microfracture — consistently appears as a predictor of poorer OATS results in long-term reviews including Pareek et al. 2016. A 'try microfracture first' strategy is therefore not as low-risk as its procedural simplicity might suggest; it may foreclose better options.

Current clinical thinking treats microfracture less as a competitor to OATS and more as a historical reference point — one that served a purpose when alternatives were fewer, but that the evidence no longer supports as a first-line choice for physically active patients with focal lesions.

Donor-site trade-offs and the size ceiling

Operating on a knee to repair one site while creating a second wound — the donor area — is the structural reality of OATS that active patients need to understand before proceeding. Harvesting plugs releases proinflammatory cytokines that drive postoperative pain, and the donor site can become a persistent source of pain or mechanical irritation in its own right. For most patients this resolves, but it is a genuine trade-off, not a minor technical footnote.

Size places the sharper constraint. As noted when describing the procedure itself, a single autograft plug suits focal lesions of roughly 1–2 cm²; beyond that, the clinician runs up against the finite supply of harvestable low-load cartilage from the same knee. Mosaicplasty — using multiple smaller plugs — extends the ceiling towards 4 cm², but the multi-plug approach carries approximately a 25% hardware removal rate and documented cases of functional decline at the donor knee, measured by Lysholm score.

When defects exceed what same-knee autograft can safely cover, the clinical conversation shifts to alternatives: fresh osteochondral allograft (OCA), cell-based techniques such as ACI or MACI, or a staged approach combining procedures. A 2025 JOCR case report offered rare direct evidence of long-term plug integrity — re-arthroscopy 18 years post-OAT found the plugs structurally intact with normal-appearing cartilage, while surrounding repaired meniscal tissue had severely deteriorated — though a single case cannot substitute for controlled long-term data.

Size limits are not a reason to rule out OATS prematurely; they are a reason to map the defect carefully through specialist assessment and arrive at the technique most likely to work for that specific anatomy.

Who gets the best results and what to do next

The patient most likely to benefit is a younger active adult or competitive athlete — typically under 35 — with a contained focal defect of 2–4 cm² or less, no prior surgery on the same knee, and a genuine need to sustain high-impact loading over years rather than months. Femoral condyle lesions carry more favourable outcomes than patellofemoral involvement; defect size and surgical history, as established in the long-term data, push results in the opposite direction.

That directional pressure makes the timing of specialist assessment clinically meaningful. Each of the key failure predictors documented in the long-term literature tends to worsen with delay — which turns a prompt evaluation from an administrative step into a functional part of the treatment strategy.

Assessment can include objective defect characterisation and, where alignment is a concern, biomechanical analysis to support surgical planning. Non-London patients can access consultant-led review without a GP referral at MSK Doctors' Sleaford and Grantham clinics; appointments are available directly at mskdoctors.com. London-based readers will find equivalent specialist access through the London Cartilage Clinic.

The strongest predictor of a good outcome the evidence keeps returning to is straightforward: catching a focal defect while it remains focal — before surrounding tissue deteriorates and the options narrow.

1. [1] Outcomes and Return to Sport After OAT for OCD of the Capitellum: Systematic Review — 2024. (2024). https://doi.org/10.1016/j.xrrt.2024.02.011 https://doi.org/10.1016/j.xrrt.2024.02.011
2. [2] Return to Sport After OATS for Unstable OCD in Baseball Players and Gymnasts — JSR 2023. (2023). https://doi.org/10.1123/jsr.2022-0446 https://doi.org/10.1123/jsr.2022-0446
3. [3] Mosaicplasty Without Debriding Recipient Site for OLT: Prospective Study — 2025. (2025). https://doi.org/10.1177/10711007251393253 https://doi.org/10.1177/10711007251393253